TECH: Bio-Techne EV/EBITDA Multiple

Corporate emblem and logo of Bio-Techne (TECH)

The robotization of Bio-Techne Corporation (TECH) protein synthesis lines may seem redundant, yet the history of the company's EV/EBITDA values on the GURU.Markets chart proves cost efficiency, where 31.93 records a new level. Despite global logistical risks and trade tariffs, the business remains resilient. Environmental responsibility through the implementation of recyclable packaging and chemical disposal finally removes any doubts regarding the long-term viability of the model.

Bio-Techne Inc. - TECH Enterprise Value to EBITDA Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for bio-techne.com (TECH)

- stock price and consensus target price:
Stock Quotes Techne Corporation|TECH - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Bio-Techne Inc.|TECH - Company Buyout Price
- issuer book value statistics:
Book Value per Share Bio-Techne|TECH - Company Net Assets|Market Cap to Net Assets Ratio bio-techne.com|TECH - Aggregate Asset Value
- company liabilities and liquidity data:
Debt to Equity Bio-Techne Corporation|TECH - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Bio-Techne|TECH - Company Cumulative Debt|Debts to Book Capitalization Bio-Techne Inc.|TECH - Company Long-Term Indebtedness|Company Short-Term Debts Bio-Techne|Quick Ratio bio-techne.com
- financial results and valuation multiples details:
TECH - Net Income|Projected Future Earnings Bio-Techne Corporation|TECH - P/E Multiple|Future Price to Earnings Bio-Techne Corporation|TECH - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Bio-Techne Inc.|TECH - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Bio-Techne|TECH - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bio-techne.com|TECH - Net earnings per share change in current year|Expected earnings per share growth for next year Bio-Techne Corporation
Initial company analysis:Techne Corporation TECH
Original product of bio-techne.com

The stability of the core management team and Kim Kelderman's focus on expanding the bioreagents portfolio minimize operational risks for Bio-Techne Corporation (TECH). This multiple relates the total business value to its ability to generate cash flow before depreciation, taxes, and interest, allowing the EV/EBITDA chart to track the balance between debt load and the asset's real profitability.

Competitor analysis for Bio-Techne Corporation

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bruker Corp|Enterprise Value to EBITDA Ratio AZTA|VREX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Semler Scientific, Inc. (SMLR)|Enterprise Value to EBITDA Ratio butterflynetwork.com BFLY|EV/EBITDA Multiple MLAB (Mesa Labs)|Quantum-Si Inc. (QSI) - Company Value to EBITDA|Nanox - EV/EBITDA Multiple|QTRX (Quanterix Inc) - Enterprise Value to Operating Income Before Depreciation|MASS: EV/EBITDA Multiple|CV - Total Company Value to Operating Income Before Depreciation Ratio|MXCT (MaxCyte) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Rapid Micro (RPID)|EV/EBITDA Multiple SEER|EV/EBITDA Multiple Hyperfine Medical (HYPR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FONAR Corporation FONR|Daxor Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDAI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIVS (Organovo Holdings)|ACON: EV/EBITDA Multiple|Company Value to EBITDA Akoya Biosciences, Inc. (AKYA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ThermoGenesis|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)